Table 4.
AEs | LEN-TACE (n = 63) |
LEN monotherapy (n = 63) |
|||
---|---|---|---|---|---|
any grade, n (%) | grade ≥3, n (%) | any grade, n (%) | grade ≥3, n (%) | ||
Fatigue | 30 (47.6) | 1 (1.6) | 24 (38.1) | 4 (6.3) | |
Hypertension | 29 (46.0) | 7 (11.1) | 24 (38.1) | 5 (7.9) | |
Decreased appetite | 27 (42.9) | 1 (1.6) | 21 (33.3) | 4 (6.3) | |
Proteinuria | 25 (39.7) | 1 (1.6) | 27 (42.9) | 3 (4.8) | |
Hypothyroidism | 22 (34.9) | 0 (0.0) | 23 (36.5) | 1 (1.6) | |
Hand-foot skin reaction | 22 (34.9) | 4 (6.3) | 22 (34.9) | 2 (3.2) | |
Liver dysfunction | 22 (34.9)* | 5 (7.9) | 12 (19.0) | 2 (3.2) | |
Diarrhea | 13 (20.6) | 1 (1.6) | 7 (11.1) | 1 (1.6) | |
Hoarseness | 10 (15.9) | 0 (0.0) | 10 (15.9) | 0 (0.0) | |
Decreased weight | 10 (15.9) | 0 (0.0) | 7 (11.1) | 0 (0.0) | |
Pyrexia | 7 (11.1) | 4 (6.3) | 4 (6.3) | 1 (1.6) | |
Thrombocytopenia | 1 (1.6) | 1 (1.6) | 1 (1.6) | 1 (1.6) | |
Encephalopathy | 1 (1.6) | 1 (1.6) | 4 (6.3) | 0 (0.0) | |
Pneumonia | 0 (0.0) | 0 (0.0) | 1 (1.6) | 1 (1.6) |
Data are presented as n (%). LEN, lenvatinib; TACE, transarterial chemoembolization.
p < 0.05, compared with LEN alone.